Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 24Neoplasms 23Ovarian Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Breast Diseases 6Recurrence 5Medulloblastoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 4Neoplasms by Site 4Lymphoma, Mantle-Cell 4Liposarcoma 4Glioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Standard of Care 2Cystectomy 2B701 protein, Human herpesvirus 6 2valrubicin 1trifluridine tipiracil drug combination 1testosterone 17 beta-cypionate 1palbociclib 1enfortumab vedotin 1atezolizumab 1Water 1Valsartan 1Urinary Diversion 1Tranexamic Acid 1Therapeutics 1Testosterone Propionate 1Sunitinib 1Stents 1Radiosurgery 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Nephrotomy 1Nephrostomy, Percutaneous 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Ice 1Hydroxychloroquine 1Health Information Exchange 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Diseases × palbociclib × Clear all
NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NiKang Therapeutics, Inc.

Phase 2 Terminated
18 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡